Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men
In the register
The register attaches this trial to NEOSH101 (Neosil), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 2
- Sponsor
- Neosil, Inc.
- Participants (registry)
- 140
- Start
- May 2007
- Primary completion
- February 2008
- Study completion
- —
- Last registry update
- May 2008
- Countries
- Germany
Conditions studied: Androgenetic Alopecia
Interventions: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
Other trials of NEOSH101
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.